ATE496889T1 - Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren - Google Patents
Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitorenInfo
- Publication number
- ATE496889T1 ATE496889T1 AT02787595T AT02787595T ATE496889T1 AT E496889 T1 ATE496889 T1 AT E496889T1 AT 02787595 T AT02787595 T AT 02787595T AT 02787595 T AT02787595 T AT 02787595T AT E496889 T1 ATE496889 T1 AT E496889T1
- Authority
- AT
- Austria
- Prior art keywords
- anthranilic acid
- treatment
- acid amide
- amide derivatives
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0126902.6A GB0126902D0 (en) | 2001-11-08 | 2001-11-08 | Organic compounds |
PCT/EP2002/012444 WO2003040102A1 (en) | 2001-11-08 | 2002-11-07 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE496889T1 true ATE496889T1 (de) | 2011-02-15 |
Family
ID=9925448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02787595T ATE496889T1 (de) | 2001-11-08 | 2002-11-07 | Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren |
Country Status (28)
Country | Link |
---|---|
US (2) | US7091224B2 (de) |
EP (1) | EP1446382B1 (de) |
JP (1) | JP2005511602A (de) |
KR (1) | KR100602977B1 (de) |
CN (1) | CN1300113C (de) |
AT (1) | ATE496889T1 (de) |
AU (1) | AU2002351909B2 (de) |
BR (1) | BR0213970A (de) |
CA (1) | CA2463968C (de) |
CO (1) | CO5580823A2 (de) |
DE (1) | DE60239073D1 (de) |
ES (1) | ES2360283T3 (de) |
GB (1) | GB0126902D0 (de) |
HR (1) | HRP20040411A2 (de) |
IL (1) | IL161747A0 (de) |
MX (1) | MXPA04004391A (de) |
NO (1) | NO327231B1 (de) |
NZ (1) | NZ532590A (de) |
PE (1) | PE20030714A1 (de) |
PL (1) | PL368416A1 (de) |
PT (1) | PT1446382E (de) |
RU (1) | RU2318811C2 (de) |
SA (1) | SA02230412B1 (de) |
TW (1) | TWI260222B (de) |
UA (1) | UA77446C2 (de) |
WO (1) | WO2003040102A1 (de) |
YU (1) | YU36004A (de) |
ZA (1) | ZA200402940B (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7307088B2 (en) * | 2002-07-09 | 2007-12-11 | Amgen Inc. | Substituted anthranilic amide derivatives and methods of use |
US7615565B2 (en) | 2002-07-31 | 2009-11-10 | Bayer Schering Pharma Aktiengesellschaft | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
US7202260B2 (en) | 2003-06-13 | 2007-04-10 | Schering Ag | VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones |
DE10327719A1 (de) * | 2003-06-13 | 2005-01-20 | Schering Ag | VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
UA89035C2 (ru) | 2003-12-03 | 2009-12-25 | Лео Фарма А/С | Эфиры гидроксамовых кислот и их фармацевтическое применение |
EP1568368A1 (de) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmazeutische Kombination enthaltend einen CDK Inhibitoren und einen VEGF Rezeptor Inhibitoren |
EP1657241A1 (de) | 2004-11-03 | 2006-05-17 | Schering Aktiengesellschaft | Neue Antranilamidpyrdinharnstoffe mit hemmender Wirkung auf VEGF-Rezeptor Kinase |
EP1655295A1 (de) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Anthranilamid-Pyridinharnstoffe als VEGF Rezeptor Kinase Inhibitoren |
US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
CA2588633A1 (en) | 2004-12-07 | 2006-06-15 | Toyama Chemical Co., Ltd. | Novel anthranilic acid derivative or salt thereof |
US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
CN101265274B (zh) * | 2007-02-16 | 2013-09-04 | 中国医学科学院药物研究所 | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 |
CA2734551A1 (en) | 2008-08-27 | 2010-03-04 | Leo Pharma A/S | Pyridine derivatives as vegfr-2 receptor and protein tyrosine kinase inhibitors |
JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
GB201322538D0 (en) | 2013-06-21 | 2014-02-05 | Immusmol Sas | Method for detecting small molecules in a sample |
CN107954893A (zh) * | 2017-11-28 | 2018-04-24 | 兰州纬寰生物科技有限公司 | 邻氨基苯甲酰胺衍生物及制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA71587C2 (uk) * | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) * | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
-
2001
- 2001-11-08 GB GBGB0126902.6A patent/GB0126902D0/en not_active Ceased
-
2002
- 2002-07-11 UA UA20040403226A patent/UA77446C2/uk unknown
- 2002-11-02 SA SA02230412A patent/SA02230412B1/ar unknown
- 2002-11-06 TW TW091132669A patent/TWI260222B/zh active
- 2002-11-06 PE PE2002001080A patent/PE20030714A1/es not_active Application Discontinuation
- 2002-11-07 JP JP2003542148A patent/JP2005511602A/ja active Pending
- 2002-11-07 DE DE60239073T patent/DE60239073D1/de not_active Expired - Lifetime
- 2002-11-07 AU AU2002351909A patent/AU2002351909B2/en not_active Ceased
- 2002-11-07 KR KR1020047007040A patent/KR100602977B1/ko not_active IP Right Cessation
- 2002-11-07 NZ NZ532590A patent/NZ532590A/en not_active IP Right Cessation
- 2002-11-07 PT PT02787595T patent/PT1446382E/pt unknown
- 2002-11-07 IL IL16174702A patent/IL161747A0/xx unknown
- 2002-11-07 RU RU2004117543/04A patent/RU2318811C2/ru not_active IP Right Cessation
- 2002-11-07 WO PCT/EP2002/012444 patent/WO2003040102A1/en active IP Right Grant
- 2002-11-07 BR BR0213970-7A patent/BR0213970A/pt not_active IP Right Cessation
- 2002-11-07 CA CA2463968A patent/CA2463968C/en not_active Expired - Fee Related
- 2002-11-07 EP EP02787595A patent/EP1446382B1/de not_active Expired - Lifetime
- 2002-11-07 CN CNB028222091A patent/CN1300113C/zh not_active Expired - Fee Related
- 2002-11-07 MX MXPA04004391A patent/MXPA04004391A/es active IP Right Grant
- 2002-11-07 US US10/494,591 patent/US7091224B2/en not_active Expired - Fee Related
- 2002-11-07 YU YU36004A patent/YU36004A/sh unknown
- 2002-11-07 PL PL02368416A patent/PL368416A1/xx not_active Application Discontinuation
- 2002-11-07 AT AT02787595T patent/ATE496889T1/de active
- 2002-11-07 ES ES02787595T patent/ES2360283T3/es not_active Expired - Lifetime
-
2004
- 2004-04-19 ZA ZA200402940A patent/ZA200402940B/en unknown
- 2004-05-07 HR HR20040411A patent/HRP20040411A2/hr not_active Application Discontinuation
- 2004-05-12 CO CO04043909A patent/CO5580823A2/es not_active Application Discontinuation
- 2004-05-26 NO NO20042187A patent/NO327231B1/no not_active IP Right Cessation
-
2006
- 2006-03-14 US US11/374,720 patent/US7482369B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE496889T1 (de) | Anthranilsäureamid derivate und deren verwendung als vegf-rezeptor tyrosin kinase inhibitoren | |
NO20054048L (no) | Ftalazinderivater for behandling av inflammatoriske sykdommer | |
PE20051171A1 (es) | Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo | |
RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
MXPA01004256A (es) | N-arilamidas del acido antranilico y del acido tioantranilico. | |
NO20070453L (no) | Kondenserte heterocykliske kinase inhibitorer | |
MY126862A (en) | Purine derivatives inhibitors of tyrosine protein kinase syk | |
DE602005024279D1 (de) | 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren | |
PT1236726E (pt) | Derivados de triazaespiro[5.5]undecano e farmacos que os contem como ingrediente activo | |
ATE453646T1 (de) | 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren | |
GT200600105A (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos. | |
BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
ATE369355T1 (de) | Pyrimidinamid derivate und deren verwendung | |
PE20061396A1 (es) | Inhibidores de quinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes a gefitinib | |
DE60108626D1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer | |
RU2007132255A (ru) | Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2 | |
MY136322A (en) | Anthranilic acid amides and pharmaceutical use thereof | |
ATE428709T1 (de) | Anthranilsäureamide und ihre pharmazeutische verwendung | |
DE602004010186D1 (de) | Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2 | |
TH58670B (th) | อนุพันธ์ 2-อะมิโน-3-(แอลคิล)-พิริมิโดน | |
TH88080B (th) | "แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน" | |
TH88080A (th) | แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน | |
UY27534A1 (es) | Amidas de ácido antranílico y uso farmacológico de las mismas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1446382 Country of ref document: EP |